- Inhibitors of the serotonin transporter protein (SERT): The design and synthesis of biotinylated derivatives of 3-(1,2,3,6-tetrahydro-pyridin-4-yl)-1H- indoles. High-affinity serotonergic ligands for conjugation with quantum dots
-
There is a growing demand for compounds with specificity for the serotonin transporter protein (SERT) that can be conjugated to cadmium selenide/zinc sulfide core shell nanocrystals. This letter describes the design and synthesis of two different biotinylated SERT antagonists that can be attached to streptavidin-coated cadmium selenide/zinc sulfide core shell nanocrystals.
- Tomlinson, Ian D.,Mason, John N.,Blakely, Randy D.,Rosenthal, Sandra J.
-
-
Read Online
- PHARMACEUTICAL COMPOUND
-
Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X2, X4, X10, and X11 may be the same or different and each is independently selected from C and N; X1, X3, X5, X6, X7, X8, and X9 may be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining X4 with the carbon atoms either side of X2 are single bonds, and are only present when X2 is absent, X3 is absent and X4 is C, and when these bonds are present the ring carbons on each side of X2 are not directly bonded to each other; each R1 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of R1 groups present is such that the valency of X1 is maintained; each R12, R13, R13', R14, R15 and R15 may be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; R16 may be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of R16 groups present is such that the valency of X2 is maintained; each R17 may be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of R17 groups present is such that the valency of X3 is maintained; each R2, R3, R4, and R5 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X6, X7, X8, and X9 are maintained; each R7, R8 and R9 may be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X10, X11, and X5 are maintained; and R6 is selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C1-C6 alkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.
- -
-
Page/Page column 141-142
(2015/06/18)
-
- Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1
-
A series of 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives was synthesized and their biological activity was evaluated. The chemical structures of the newly prepared compounds were confirmed by 1H NMR, 13C NMR and ESI-HRMS spectra data. All tested compounds proved to be potent 5-HT1A receptor and serotonin transporter protein (SERT) ligands. Among them, compounds 15, 18, 19 and 30 showed significant affinity for 5-HT1A and SERT. Computer docking simulations carried out for compounds 15, 31 and 32 to models of 5-HT1A receptor and SERT confirm the results of biological tests. Due to high affinity for the 5-HT1A receptor and moderate affinity for SERT, compounds 31, 32, 35, and 37 were evaluated for their affinity for D2L, 5-HT6, 5-HT 7 and 5-HT2A receptors. In vivo tests, in turn, resulted in determining the functional activity of compounds 15, 18, 19 and 30 to the 5-HT1A receptor. The results of these tests indicate that all of the ligands possess properties characteristic of 5-HT1A receptor agonists.
- Wróbel, Martyna Z.,Chodkowski, Andrzej,Herold, Franciszek,Gomó?ka, Anna,Kleps, Jerzy,Mazurek, Aleksander P.,Pluciński, Franciszek,Mazurek, Andrzej,Nowak, Gabriel,Siwek, Agata,Stachowicz, Katarzyna,S?awin?ska, Anna,Wolak, Ma?gorzata,Szewczyk, Bernadeta,Sata?a, Grzegorz,Bojarski, Andrzej J.,Tur?o, Jadwiga
-
p. 484 - 500
(2013/07/25)
-
- Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6- tetrahydropyridines as 5-HT2C agonists
-
A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein.
- Conway, Richard J.,Valant, Celine,Christopoulos, Arthur,Robertson, Alan D.,Capuano, Ben,Crosby, Ian T.
-
supporting information; experimental part
p. 2560 - 2564
(2012/05/05)
-
- DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS
-
Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.
- -
-
Page/Page column 7; 87-90
(2011/12/02)
-
- Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
-
The present invention relates to a group of novel tetrahydropyridin-4-yl indoles with a dual mode of action: serotonin reuptake inhibition and affinity for dopamine-D2 receptors, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said tetrahydropyridin-4-yl indoles. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The invention relates to novel tetrahydropyridin-4-yl indoles of the formula. and tautomers, stereoisomers, prodrugs, N-oxides, pharmacologically acceptable salts, hydrates and solvates thereof, wherein: R1 is hydrogen, halogen, alkyl(C1-3) or alkoxy(C1-3), CN or CF3, R2 is hydrogen or alkyl(C1-3), R3 is hydrogen or alkyl(C1-3), Z is hydrogen or alkyl(C1-3), alkoxy(C1-3) or alkylthio(C1-3), A is hydrogen or alkyl(C1-3), or A and Z together form a saturated or (partly) unsaturated 5- or 6-membered ring which may be substituted with halogen, alkyl (C1-3) or phenyl, in which ring Z represents carbon, sulfur of nitrogen.
- -
-
Page/Page column 3
(2010/11/08)
-
- 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS
-
The invention relates to 4-substituted 1-aminocyclohexane derivatives of general formula (I), to a method for the production thereof, to medicaments containing said compounds and to the utilization of 4-substituted 1-aminocyclohexane derivatives for the production of medicaments.
- -
-
Page/Page column 72-73
(2008/06/13)
-
- Synthesis and structure-activity relationships of novel histamine H 1 antagonists: Indolylpiperidinyl benzoic acid derivatives
-
A series of indolylpiperidinyl derivatives were prepared and evaluated for their activity as histamine H1 antagonists. Structure-activity relationship studies were directed toward improving in vivo activity and pharmacokinetic profile of our first lead (1). Substitution of fluorine in position 6 on the indolyl ring led to higher in vivo activity in the inhibition of histamine-induced cutaneous vascular permeability assay but lower selectivity toward 5HT2 receptor. Extensive optimization was carried out within this series and a number of histamine H1 antagonists showing potency and long duration of action in vivo and low brain penetration or cardiotoxic potential were identified. Within this novel series, indolylpiperidines 15, 20, 48, 51 and 52 exhibited a long half-life in rat and have been selected for further preclinical evaluation.
- Fonquerna, Silvia,Miralpeix, Montse,Pagès, Lluís,Puig, Carles,Cardús, Arantxa,Antón, Francisca,Cárdenas, álvaro,Vilella, Dolors,Aparici, Mónica,Calaf, Elena,Prieto, José,Gras, Jordi,Huerta, Josep M.,Warrellow, Graham,Beleta, Jorge,Ryder, Hamish
-
p. 6326 - 6337
(2007/10/03)
-
- INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS
-
The invention relates to indolyl piperidinyl derivatives of formula (I) wherein: A1 represents an alkylene, alkyleneoxy, alkylenethio, alkanoylene or hydroxyalkylene group; A2 represents an alkylene, alkyleneoxy, alkylenethio, alkanoylene or an alkyleneoxyalkylene group; W1 represents a phenylene, furanylene or pyridinylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; W2 represents a 3-10 membered monocyclic or bicyclic group containing from 1 to 3 heteroatoms said group being unsubstituted or substituted by one or more halogen atoms, alkyl groups, alkoxy groups and/or oxo groups; R1 represents a hydrogen or halogen atom or an alkyl, alkoxy or methylamino group; and R2 represents a carboxyl group; and pharmaceutically acceptable salts thereof; to processes for their preparation; to pharmaceutical compositions containing them; and to their medical use as antihistaminic and antiallergic agents.
- -
-
-
- NEW INDOLYLPIPERIDINE DERIVATIVES AS POTENT ANTIHISTAMINIC AND ANTIALLERGIC AGENTS
-
This invention is directed to new potent and selective antagonists of H1 histamine receptors having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy as antiallergic agents.
- -
-
-
- INDOLE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS
-
Disclosed are novel compounds of the formula I wherein M1 is CH or N and M2 is C(R3) or N; R1 is optionally substituted indolyl or an aza derivative thereof; R2 is optionally substituted aryl or heteroaryl; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of formula I in combination with a H1 receptor antagonist.
- -
-
-
- Indolylpiperidine derivatives as antihistaminic and antiallergic agents
-
Indolylpiperidine compounds of formula (I) wherein: A1 represents an alkylene, alkyleneoxy, alkylenethio, alkanoyl or hydroxyalkylene group; A2 represents a single bond, an alkylene or alkenylene group; W represents a single bond or a phenylene or furanylene group which is unsubstituted or substituted by one or more halogen atoms, alkoxy groups and/or alkyl groups; R1 represents a hydrogen atom or an alkyl, alkenyl, alkynyl, alkoxyalkyl, alkenyloxyalkyl, alkynyloxyalkyl alkoxy-alkoxyalkyl, phenylalkyl group wherein the phenyl ring is unsubstituted or substituted by one or more halogen atoms or alkyl, alkoxy or arylalkoxy groups, or a cycloalkylalkyl group wherein the cycloalkyl group is unsubstituted or substituted by one or more halogen atoms, alkyl groups or alkoxy groups; R2 represents a hydrogen or halogen atom or an alkyl or alkoxy group; and R3 represents a carboxyl group or a tetrazolyl group; and pharmaceutically acceptable salts thereof, process for their preparation and medicinal use.
- -
-
-
- Process for the synthesis of derivatives of 2, 3-dihydro-1, 4-dioxino- [2, 3-f] quinoline
-
Methods of preparing compounds of Formula I are provided.
- -
-
-
- Studies toward the discovery of the next generation of antidepressants. Part 2: Incorporating a 5-HT1A antagonist component into a class of serotonin reuptake inhibitors
-
The design and synthesis of a novel series of indole derivatives (9) having dual 5-HT transporter reuptake and 5-HT1A antagonist activity are described.
- Mewshaw, Richard E.,Meagher, Kristin L.,Zhou, Ping,Zhou, Dahui,Shi, Xiaojie,Scerni, Rosemary,Smith, Deborah,Schechter, Lee E.,Andree, Terrance H.
-
p. 307 - 310
(2007/10/03)
-
- Dipeptides which promote release of growth hormone
-
Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. STR1
- -
-
-
- 4-(Indolyl-3)-1-(benzimidazolonylalkyl)-piperidines, a novel group of potential antiallergy compounds
-
A group of indolyl-benzimidazolone-piperidines is described and the structure-activity with reference to the passive cutaneous anaphylaxis (PCA) in rats is discussed. Compound 7b, 4-(indolyl-3)-1-(benzimidazolonyl-propyl)-piperidine, which has the highest potency in this test, was studied in more detail with regard to antihistaminic and secretory cell stabilization properties.
- Freter,Fuchs,Barsumian,Oliver
-
p. 272 - 276
(2007/10/02)
-
- Tetrahydropyridinyl indoles
-
Novel tetrahydropyridinyl indoles of the formula STR1 wherein R' is selected from the group consisting of hydrogen, halogen and alkoxy of 1 to 3 carbon atoms, R1 and R2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 3 carbon atoms and X' is selected from the group consisting of alkyl of 1 to 6 carbon atoms, cycloalkyl of 4 to 7 carbon atoms, alkenyl and alkynyl of 2 to 5 carbon atoms and aralkyl of 7 to 12 carbon atoms with the proviso that when X' is methyl, at least one of R', R1 and R2 contain more than one carbon atom and when X' is benzyl, at least one of R', R1 and R2 must not be hydrogen and their non-toxic, pharmaceutically acceptable acid addition salts having antidepressive and neuroleptic properties as well as antiemetic properties.
- -
-
-
- Treating psychic disorders with piperidyl-indoles
-
Novel piperidyl-indoles of the formula STR1 wherein X is selected from the group consisting of fluorine, chlorine and bromine when Y and Z are hydrogen or together form a double bond and X is selected from the group consisting of hydrogen and alkoxy of 1 to 3 carbon atoms when Y and Z form a double bond and their non-toxic, pharmaceutically acceptable acid addition salts having antidepressant, antiemetic and antiparkinsonian activity and their preparations and novel intermediates therefore.
- -
-
-
- Novel 1,4-benzodioxanes
-
Novel 1,4-benzodioxanes of the formula STR1 wherein R' is selected from the group consisting of hydrogen, alkoxy of 1 to 5 carbon atoms, chlorine, bromine and fluorine, R1 and R2 are individually selected from the group consisting of hydrogen and alkyl of 1 to 5 carbon atoms and Y and Z are hydrogen or together form a double bond in the form of their racemic mixtures or optically active isomers and their non-toxic, pharmaceutically acceptable acid addition salts having antihypertensive activity and a novel process and novel intermediates for their preparation.
- -
-
-